Bladder Cancer: Treatment in the Metastatic Setting

Opinion
Video

Focusing on the metastatic setting, the expert panel discusses advanced kidney cancer treatment practices, highlighting recent data that are informing treatment decisions.

Recent Videos
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Experts on bladder cancer
Related Content
Discerning the Best Frontline, Personalized Treatment in Urothelial Carcinoma

Discerning the Best Frontline, Personalized Treatment in Urothelial Carcinoma

Alex Biese
November 20th 2024
Article

“How do we personalize and improve patient selection for frontline treatment now that patients are living, on average, more than 2 years with this aggressive cancer?” said David H. Aggen, MD, PhD

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Matthew Fowler;Jun Gong, MD
March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Disease-free survival and overall survival were lower with extended lymphadenectomy compared with standard lymphadenectomy.

Extended Lymphadenectomy Does Not Improve DFS/OS in Bladder Cancer

Tim Cortese
November 6th 2024
Article

Disease-free survival and overall survival were lower with extended lymphadenectomy compared with standard lymphadenectomy.

Emerging Immunotherapy Approaches For Urothelial Cancer

Emerging Immunotherapy Approaches For Urothelial Cancer

Petros Grivas, MD, PhD
February 4th 2019
Podcast

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

The decision is backed by robust efficacy data from the phase 3 ENVISION trial, evaluating UGN-102 in patients with non-muscle invasive bladder cancer.

FDA Accepts New Drug Application for UGN-102 for Bladder Cancer

Roman Fabbricatore
October 16th 2024
Article

The decision is backed by robust efficacy data from the phase 3 ENVISION trial, evaluating UGN-102 in patients with non-muscle invasive bladder cancer.

TAS-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.

TAR-200 Study in Muscle-Invasive Bladder Cancer Discontinued

Ariana Pelosci
October 9th 2024
Article

TAR-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.